Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD

Table 1

Demographic and clinical characteristics of the patient cohorts profiled for expression of inflammation- and immunity-related genes, values marked by asterisk (∗) are given as average ± SD. All subjects qualified for NAFLD had no history of alcohol abuse. No patients were taking thiazolidinediones (TZDs) or medication for gastritis.

Demographic or clinical parameter	Mean ± SD, or % (𝑁=20)
BMI (∗)	48.67 ± 8.95
AST, U/L (∗)	24.20 ± 7.13
ALT, U/L (∗)	31.25 ± 12.99
Total cholesterol, mg/dL (∗)	185.40 ± 76.61
HDL, mg/dL (∗) females	53 ± 17
HDL, mg/dL (∗) males	39.67 ± 7.09
Triglyceride, mg/dL (∗)	196.75 ± 107.28
Glucose, mg/dL (∗)	108.70 ± 36.20
Age, yr	43.44 ± 10.63
Hypertension	55% (𝑁=11)
Smoking	5% (𝑁=1)
Gender (females)	75% (𝑁=15)
Race (Caucasian)	80% (𝑁=16)
Advanced inflammation (score ≥ 3)	50% (𝑁=10)
NASH	65% (𝑁=13)
Advanced steatosis	60% (𝑁=8)
Fibrosis	75% (𝑁=15)
Steatosis with advanced inflammation	50% (𝑁=10)
NASH with advanced inflammation	30% (𝑁=6)
Gastritis	45% (𝑁=9)

SD: standard deviation; BMI: body mass index; NASH: nonalcoholic steatohepatitis; AST: aspartate aminotransferase; ALT: alanine transaminase; HDL: high-density lipoprotein.